001     304997
005     20251118090749.0
024 7 _ |a 10.1016/j.canlet.2025.218068
|2 doi
024 7 _ |a pmid:41016679
|2 pmid
024 7 _ |a 0304-3835
|2 ISSN
024 7 _ |a 1872-7980
|2 ISSN
037 _ _ |a DKFZ-2025-01988
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Mills, Taylor S
|b 0
245 _ _ |a MRC2 expression modulates metabolism in acute myeloid leukemia stem cells.
260 _ _ |a Amsterdam [u.a.]
|c 2025
|b Elsevier Science
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1763453227_1939190
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a Volume 635, 28 December 2025, 218068
520 _ _ |a Leukemic stem cells (LSC) are well recognized for their essential roles in acute myeloid leukemia (AML) initiation and relapse. LSC can be distinguished from non-LSC AML cells by the expression of specific cell surface markers, but there is considerable phenotypic heterogeneity among LSC in AML. Here, using primary patient samples, we report that mannose receptor C-type 2 (MRC2) can be used to enrich for LSC across various AML subtypes. When compared to MRC2- AML cells isolated from the same patient samples, MRC2+ leukemic subpopulations show increased in vitro clonogenic capacity, a stemness transcriptomic signature, and enhanced leukemic capacity in mouse xenograft models. Further, we find that MRC2 is functional on AML cells, and enables their robust uptake of collagen, which supports their glycolytic metabolism. In sum these data highlight the use of functional surface markers to distinguish LSC in AML, and how they can yield insight into their unique characteristics.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a MRC2
|2 Other
650 _ 7 |a acute myeloid leukemia
|2 Other
650 _ 7 |a glycolysis
|2 Other
650 _ 7 |a leukemia stem cells
|2 Other
650 _ 7 |a mannose receptor c-type2
|2 Other
650 _ 7 |a metabolism
|2 Other
700 1 _ |a Arnone, Marlon
|b 1
700 1 _ |a Görsch, Elsa
|b 2
700 1 _ |a Poeschel, Simone
|b 3
700 1 _ |a Winter, Stefan
|b 4
700 1 _ |a Kuebler, Jessica
|b 5
700 1 _ |a Kimmich, Lucca M
|b 6
700 1 _ |a Büttner, Florian A
|b 7
700 1 _ |a Weller, Jan
|b 8
700 1 _ |a Rudat, Saskia S
|b 9
700 1 _ |a Mix, Lucas
|b 10
700 1 _ |a Schroeder, Jan C
|b 11
700 1 _ |a Paczulla Stanger, Anna M
|b 12
700 1 _ |a Schwab, Matthias
|0 P:(DE-He78)0321c153233e619c095d93d9d5546c9d
|b 13
700 1 _ |a Lengerke, Claudia
|0 P:(DE-HGF)0
|b 14
773 _ _ |a 10.1016/j.canlet.2025.218068
|g p. 218068 -
|0 PERI:(DE-600)2004212-7
|p 218068
|t Cancer letters
|v 635
|y 2025
|x 0304-3835
909 C O |p VDB
|o oai:inrepo02.dkfz.de:304997
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)0321c153233e619c095d93d9d5546c9d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2025
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-16
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCER LETT : 2022
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-16
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-16
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-16
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CANCER LETT : 2022
|d 2024-12-16
920 1 _ |0 I:(DE-He78)TU01-20160331
|k TU01
|l DKTK Koordinierungsstelle Tübingen
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)TU01-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21